Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)

Nicole McCarthy, Frances Boyle, Nicholas Zdenkowski, James Bull, Eugene Leong, Andrew Simpson, George Kannourakis, Prudence Francis, Jacquie Chirgwin, Ehtesham Abdi, Val Gebski, Anne-Sophie Veillard, Diana Zannino, Nicholas Wilcken, Linda Reaby, Dianne F Lindsay, Heath D Badger, John F Forbes

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)


Neoadjuvant chemotherapy has a sound rationale for use in women with large operable breast cancer, and achievement of pathological complete response (pCR) is prognostic. Epirubicin and cyclophosphamide followed by docetaxel is a standard chemotherapy regimen for early breast cancer. Inmetastatic breast cancer the combination of gemcitabine and a taxane has shown promising results. This phase II study investigated the efficacy and safety of incorporating gemcitabine into neoadjuvant therapy.
Original languageEnglish
Pages (from-to)142 - 151
Number of pages10
JournalThe Breast
Issue number2
Publication statusPublished - 2014

Cite this